197 results
425
INFIQ
Infinity Pharmaceuticals, Inc.
3 Jul 23
Business combination disclosure
4:57pm
of the acquisition targets were directly comparable to Infinity, and none had a lead product candidate directly comparable to eganelisib. Since the Merger … given the size and equity value of the acquirers relative to the acquisition targets.
Under the heading “THE MERGER—Opinion of Infinity Financial
8-K
INFIQ
Infinity Pharmaceuticals, Inc.
3 Jul 23
Other Events
4:55pm
of the acquisition targets were directly comparable to Infinity, and none had a lead product candidate directly comparable to eganelisib. Since the Merger … given the size and equity value of the acquirers relative to the acquisition targets.
Under the heading “THE MERGER—Opinion of Infinity Financial
DEFM14A
INFIQ
Infinity Pharmaceuticals, Inc.
6 Jun 23
Proxy related to merger
4:31pm
, objectives and targets over the applicable periods. As a result, there can be no assurance that the underlying assumptions will prove to be accurate … and targets over the applicable period. Accordingly, there can be no assurance that the MEI Projections will be realized and actual results may vary
8-K
EX-99.2
1irtkdh2c2crn8t
27 Jul 21
Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides
7:43am